Infinity Pharmaceuticals has expanded its clinical collaboration with Bristol-Myers Squibb evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer (TNBC) who have not been previously exposed to anti-PD-1 or anti-PD-L1 therapy. IPI-549 is an oral, selective phosphoinositide-3-kinase gamma (PI3K-gamma) inhibitor which targets immune-suppressive tumor macrophages. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. IPI-5...